Deutsche Bank AG (German pronunciation: [ˈdɔʏtʃə ˈbaŋk ʔaːˈɡeː] , lit. 'German Bank') is a German multinational investment bank and financial services company headquartered in Frankfurt. It is dual-listed on the Frankfurt Stock Exchange and the New York Stock Exchange.
Deutsche Bank was founded in ...
The downgrade by Deutsche Bank highlights the heightened patent risk for Harmony Biosciences' flagship drug Wakix, potentially shortening its exclusivity window and impacting future earnings. Investors now face greater uncertainty over the company's valuation and growth prospects.
Context & Background
Harmony Biosciences faces a patent challenge from AET Pharma over Wakix.
Deutsche Bank lowered the price target from $47 to $31 and changed the rating to Hold.
Shares fell 15% after the court verdict, reflecting investor concern.
What Happens Next
Harmony will likely defend its patents and may negotiate a settlement to delay generic entry. The company will monitor court developments and could adjust revenue guidance if the patent dispute escalates. Investors will watch for any changes in the regulatory and legal landscape that could affect Wakix's market position.
Frequently Asked Questions
What is the impact of the patent challenge on Wakix's exclusivity?
The challenge could force Wakix to lose exclusivity as early as 2026 instead of the previously expected 2030, opening the market to generics.
How did the court ruling affect Harmony's stock price?
The verdict led to a 15% drop in the stock by Friday's close and a 19% decline over the past week.
What are Harmony's future revenue expectations?
The company projects Wakix revenue of $1.0 to $1.04 billion for 2026, potentially reaching blockbuster status.
What steps is Harmony taking to mitigate the patent risk?
Harmony is reviewing its patent portfolio, engaging in legal defense, and partnering with Beacon Biosignals to strengthen clinical data for other indications.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Five things to watch in markets in the week ahead Trump’s 15% global tariff; Waller to speak; oil drops - what’s moving markets U.S. stock futures drop on Trump tariff turmoil; Nvidia earnings in spotlight Novo Nordisk and Netflix fall premarket; Eli Lilly and Domino’s Pizza rise (South Africa Philippines Nigeria) Deutsche Bank cuts Harmony Biosciences stock rating on patent risk By Investing.com Analyst Ratings Published 02/23/2026, 07:46 AM Deutsche Bank cuts Harmony Biosciences stock rating on patent risk 0 HRMY -15.21% Investing.com - Deutsche Bank downgraded Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) to Hold from Buy and lowered its price target to $31.00 from $47.00. The downgrade follows a bench trial that concluded Friday, February 20, 2026, in Delaware District Court between Harmony Biosciences and AET Pharma, a generics manufacturer challenging the intellectual property of Wakix, the company’s lead drug. Bloomberg and sell-side firms reported the judge leaned negatively toward Harmony Biosciences during the proceedings. Shares of Harmony Biosciences fell 15% by Friday’s close, with InvestingPro data showing a 19% decline over the past week. The trial outcome represents a threat to Wakix’s loss of exclusivity, which was previously expected in 2030 but could now occur as early as 2026. AET Pharma filed an Abbreviated New Drug Application under Paragraph IV challenging the patents covering Wakix, which treats narcolepsy and other sleep disorders with the active ingredient pitolisant. Despite the legal uncertainty, the stock trades at a P/E ratio of 9.2 and appears undervalued according to InvestingPro analysis. Deutsche Bank reviewed Wakix’s FDA Orange Book listings, patents filed with the U.S. Patent and Trademark Office, and publicly available court documents. The firm concluded that Harmony Biosciences faces a higher level of intellectual property risk than is typical from generic drug filers. ...
